Follow us on Twitter
Find us on Facebook
Blood test may predict course of MS
31 Aug 2009
Scientists have discovered a blood test that could predict the course of multiple sclerosis (MS), or even indicate who is likely to develop the condition after a first MS-like attack.
The results of the study suggest that differing antibody levels produced in response to the common virus Epstein Barr Virus (EBV), may predict the course of MS.
If proven in further studies, this would be the first credible biological indicator, or biomarker, identified for MS that could predict disability progression from a simple blood test.
The innovative work was carried out at the Institute of Neurology, UCL and the Institute of Cell and Molecular Biology, Barts and The London and was funded by the MS Society.
It is hoped the findings will aid the development of better ways to predict who goes on to develop MS after initial MS-like symptoms and help in identifying more effective therapies for the 100,000 people living with MS in the UK.
The paper’s lead author, Clinical Research Fellow Dr Rachel Farrell, said: "All the participants in our study had previous history of infection with EBV, which has been shown in other studies and is not surprising given that a large majority of the adult population is infected with EBV.
"What was surprising is that the levels of a molecule in the blood called anti-EBNA-1 IgG, induced by the virus, were associated with the activity of MS.
"The results of this work show that those participants who had new areas of MS damage in the brain also had high levels of the anti-EBNA-1 IgG molecule in their blood."
The researchers received funding of nearly £35,000 from the MS Society's Innovation Research grant scheme.
The authors of the study, published in the journal Neurology, concluded that anti-EBNA-1 IgG is a potential biomarker in MS that might be useful in predicting disability and progression.
They added that the work needed to be validated in larger studies and in combination with other as yet unidentified biomarkers.
Dr Susan Kohlhaas, Research Communications Officer at the MS Society, said: "We’re delighted that such an interesting study has produced these valuable results that will give scientists a new avenue of MS research to explore.
"Identifying biomarkers of MS is a key area of research and this work is a stepping stone on the path to mapping out the course of the condition and potentially determining prognosis.
"People with MS find the uncertainty of what the future holds very daunting so more knowledge about what might lie in store could be a big help."
Read more in Research News
If proven in further studies, this would be the first credible biological indicator, or biomarker, identified for MS that could predict disability progression from a simple blood test.
The innovative work was carried out at the Institute of Neurology, UCL and the Institute of Cell and Molecular Biology, Barts and The London and was funded by the MS Society.
It is hoped the findings will aid the development of better ways to predict who goes on to develop MS after initial MS-like symptoms and help in identifying more effective therapies for the 100,000 people living with MS in the UK.
The paper’s lead author, Clinical Research Fellow Dr Rachel Farrell, said: "All the participants in our study had previous history of infection with EBV, which has been shown in other studies and is not surprising given that a large majority of the adult population is infected with EBV.
"What was surprising is that the levels of a molecule in the blood called anti-EBNA-1 IgG, induced by the virus, were associated with the activity of MS.
"The results of this work show that those participants who had new areas of MS damage in the brain also had high levels of the anti-EBNA-1 IgG molecule in their blood."
The researchers received funding of nearly £35,000 from the MS Society's Innovation Research grant scheme.
The authors of the study, published in the journal Neurology, concluded that anti-EBNA-1 IgG is a potential biomarker in MS that might be useful in predicting disability and progression.
They added that the work needed to be validated in larger studies and in combination with other as yet unidentified biomarkers.
Dr Susan Kohlhaas, Research Communications Officer at the MS Society, said: "We’re delighted that such an interesting study has produced these valuable results that will give scientists a new avenue of MS research to explore.
"Identifying biomarkers of MS is a key area of research and this work is a stepping stone on the path to mapping out the course of the condition and potentially determining prognosis.
"People with MS find the uncertainty of what the future holds very daunting so more knowledge about what might lie in store could be a big help."
Read more in Research News
BACK TO TOP
